Summary

Japan Pharmaceuticals Market Summary, Competitive Analysis and Forecast to 2026

Summary

Pharmaceuticals in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2016-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
- The Japanese pharmaceuticals market had total revenues of $89.6 billion in 2021, representing a compound annual growth rate (CAGR) of 8% between 2016 and 2021.
- Japan’s aging population is likely to balance the downwards pressure on drug prices, helping to maintain growth in the market over the forecast period.
- The Japanese government believes that by promoting innovations in healthcare to match economic growth, the costs of the aging population will not rise as fast as they have done previously.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Japan
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Japan
- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Japan pharmaceuticals market with five year forecasts by both value and volume

Reasons to Buy

- What was the size of the Japan pharmaceuticals market by value in 2021?
- What will be the size of the Japan pharmaceuticals market in 2026?
- What factors are affecting the strength of competition in the Japan pharmaceuticals market?
- How has the market performed over the last five years?
- How large is Japan’s pharmaceuticals market in relation to its regional counterparts?

ページTOPに戻る

Table of Contents

Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Geography segmentation
1.4. Market share
1.5. Market rivalry
1.6. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Market share
7.2. Who are the leading players?
7.3. What strategies do leading players follow?
7.4. What are the weaknesses of leading players?
7.5. Is there any significant M&A activity on the horizon for next year?
8 Company Profiles
8.1. Daiichi Sankyo Co Ltd
8.2. Astellas Pharma Inc.
8.3. Mitsubishi Tanabe Pharma Corporation
8.4. Takeda Pharmaceutical Company Limited
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine